InsiderTrades.com logo

QTTB Insider Trading

Insider Ownership Percentage: 16.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $6,488.28

Q32 Bio Insider Trading History Chart

This chart shows the insider buying and selling history at Q32 Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Q32 Bio Share Price & Price History

Current Price: $3.14
Price Change: ▼ Price Decrease of -0.06 (-1.88%)
As of 01/16/2025 05:00 PM ET

This chart shows the closing price history over time for QTTB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Q32 Bio Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/25/2024Paul AllowayInsiderSell268$24.21$6,488.282,596View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Q32 Bio (NASDAQ:QTTB)

31.32% of Q32 Bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at QTTB by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Q32 Bio Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/27/2024Franklin Resources Inc.4,857$0.23M0.0%N/A0.040%Search for SEC Filing on Google Icon
11/19/2024Barclays PLC10,443$0.47M0.0%+105.2%0.086%Search for SEC Filing on Google Icon
11/16/2024Geode Capital Management LLC131,768$5.88M0.0%+22.4%1.082%Search for SEC Filing on Google Icon
11/15/2024Barclays PLC10,443$0.47M0.0%+105.2%0.086%Search for SEC Filing on Google Icon
11/15/2024Jane Street Group LLC16,437$0.73M0.0%N/A0.135%Search for SEC Filing on Google Icon
11/15/2024State Street Corp110,164$4.92M0.0%+35.5%0.904%Search for SEC Filing on Google Icon
11/15/2024Point72 Asset Management L.P.76,685$3.42M0.0%N/A0.630%Search for SEC Filing on Google Icon
11/14/2024Eventide Asset Management LLC190,000$8.48M0.1%N/A1.560%Search for SEC Filing on Google Icon
11/14/2024MetLife Investment Management LLC3,563$0.16M0.0%N/A0.029%Search for SEC Filing on Google Icon
11/13/2024BNP Paribas Financial Markets1,298$58K0.0%+199.1%0.011%Search for SEC Filing on Google Icon
11/13/2024FMR LLC426,302$19.02M0.0%+137.3%3.500%Search for SEC Filing on Google Icon
10/23/2024Values First Advisors Inc.741$33K0.0%N/A0.006%Search for SEC Filing on Google Icon
8/13/2024Ensign Peak Advisors Inc64,481$1.16M0.0%+150.6%0.540%Search for SEC Filing on Google Icon
8/9/2024Renaissance Technologies LLC14,764$0.27M0.0%N/A0.124%Search for SEC Filing on Google Icon
8/9/2024Harvard Management Co. Inc.162,965$2.93M0.2%N/A1.365%Search for SEC Filing on Google Icon
8/1/2024Rhumbline Advisers7,658$0.14M0.0%+11,681.5%0.064%Search for SEC Filing on Google Icon
7/26/2024Bank of New York Mellon Corp17,569$0.32M0.0%N/A0.147%Search for SEC Filing on Google Icon
5/17/2024Ikarian Capital LLC22,335$0.38M0.0%N/A0.685%Search for SEC Filing on Google Icon
5/15/2024ARCH Venture Management LLC320,482$5.46M6.5%N/A9.831%Search for SEC Filing on Google Icon
5/15/2024Affinity Asset Advisors LLC27,777$0.47M0.1%N/A0.852%Search for SEC Filing on Google Icon
5/14/2024Platinum Investment Management Ltd.109,964$1.87M0.1%N/A3.373%Search for SEC Filing on Google Icon
5/10/2024Acadian Asset Management LLC3,695$62K0.0%N/A0.113%Search for SEC Filing on Google Icon
5/10/2024Vanguard Group Inc.107,752$1.84M0.0%N/A3.305%Search for SEC Filing on Google Icon
5/6/2024Atlas Venture Life Science Advisors LLC2,092,106$35.65M3.3%N/A64.254%Search for SEC Filing on Google Icon
5/3/2024Carlyle Group Inc.1,102,741$18.07M1.1%N/A33.826%Search for SEC Filing on Google Icon
4/23/2024BML Capital Management LLC24,894$0.42M0.3%N/A0.764%Search for SEC Filing on Google Icon
4/22/2024Vivo Capital LLC370,068$6.31M0.5%N/A11.366%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Q32 Bio logo
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
Read More on Q32 Bio

Today's Range

Now: $3.14
Low: $3.02
High: $3.23

50 Day Range

MA: $16.49
Low: $3.07
High: $47.46

52 Week Range

Now: $3.14
Low: $2.99
High: $53.79

Volume

216,729 shs

Average Volume

337,363 shs

Market Capitalization

$38.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Q32 Bio?

Q32 Bio's top insider investors include:
  1. Paul Alloway (Insider)
Learn More about top insider investors at Q32 Bio.